

June 22, 2012



# Boston Therapeutics Completes Enrollment in Phase II Clinical Trial to Evaluate PAZ320 in Patients With Type 2 Diabetes

MANCHESTER, NH -- (MARKETWIRE) -- 06/22/12 -- **Boston Therapeutics, Inc.** (OTCQB: BTHE) (OTCBB: BTHE) ("**Boston Therapeutics**" or "**The Company**"), a developer of complex carbohydrates to treat diabetes and inflammatory diseases, today announced it has completed enrollment in a Phase II clinical trial to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with Type 2 diabetes at Dartmouth-Hitchcock Medical Center in Lebanon, NH. PAZ320 is a non-systemic chewable tablet designed to reduce post-meal elevation of blood glucose.

On April 10, 2012, the Company announced that interim data analysis of the Phase II clinical trial showed that there were no serious adverse events from PAZ320. 24 patients with Type 2 diabetes were included in the open label, dose escalation crossover trial. The patients were adults age 18-75 with Type 2 diabetes, on insulin or oral agents, with a body mass index of 25-40 kg/m<sup>2</sup> and with an A1C of less than or equal to 9%. The A1C test is a blood test that provides information about a person's average levels of blood glucose, also called blood sugar, over the past three months. The Company expects to report Phase II final results by September 2012.

"In pre-clinical models, we saw significant reductions of post-meal elevation of glucose with PAZ320," said David Platt, PhD, Chairman and Chief Executive Officer, Boston Therapeutics. "It is important to manage glucose levels given the many complications that result from uncontrolled diabetes. We are hopeful that PAZ320 will help the millions of people who have high blood sugar and diabetes."

## **About PAZ320**

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release them into the bloodstream.

## **About Dartmouth-Hitchcock Medical Center**

Dartmouth-Hitchcock Medical Center is a nationally ranked academic medical center located in Lebanon, NH and includes the Dartmouth-Hitchcock Clinic and the Dartmouth Medical School, one of America's oldest and most respected medical schools.

## **About Boston Therapeutics, Inc.**

Boston Therapeutics, headquartered in Manchester, NH, (OTCBB: BTHE) is a leader in the

field of complex carbohydrates, a specialized field involving understanding the importance of the role that carbohydrates play in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose; PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN™, a systemic, injectable complex carbohydrate-based oxygen therapeutic for limb ischemia. More information is available at [www.bostonti.com](http://www.bostonti.com).

### ***Forward-Looking Statements***

The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this press release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

### ***Contact:***

Boston Therapeutics, Inc.  
Anthony Squeglia  
Phone: 603-935-9799  
Email [anthony.squeglia@bostonti.com](mailto:anthony.squeglia@bostonti.com)  
[www.bostonti.com](http://www.bostonti.com)

Investor Relations:  
MZ Group  
Scott Powell  
Senior Vice President  
Phone: 212-301-7130  
Email: [scott.powell@mzgroup.us](mailto:scott.powell@mzgroup.us)  
[www.mz-ir.com](http://www.mz-ir.com)